Cargando…

Effectiveness of benralizumab for allergic and eosinophilic predominant asthma following negative initial results with omalizumab

A 64‐year‐old woman, who had presented with a 30‐year history of refractory asthma, and been treated with anti‐allergic drug therapy, inhaled corticosteroids, a long‐acting beta‐agonist, and a long‐acting muscarinic antagonist. She had been characterized as an allergic, eosinophilic asthmatic. Altho...

Descripción completa

Detalles Bibliográficos
Autores principales: Minami, Daisuke, Kayatani, Hiroe, Sato, Ken, Fujiwara, Keiichi, Shibayama, Takuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6249091/
https://www.ncbi.nlm.nih.gov/pubmed/30479771
http://dx.doi.org/10.1002/rcr2.388
Descripción
Sumario:A 64‐year‐old woman, who had presented with a 30‐year history of refractory asthma, and been treated with anti‐allergic drug therapy, inhaled corticosteroids, a long‐acting beta‐agonist, and a long‐acting muscarinic antagonist. She had been characterized as an allergic, eosinophilic asthmatic. Although omalizumab was tried initially, it was found to be insufficient. We began treatment with benralizumab. The asthma symptom control and sinusitis were improved immediately. Benralizumab was effective for overlapping patient population following negative initial results with omalizumab.